Study on SNV4818 for Adults with Advanced Solid Tumors

Sponsor: Pikavation Therapeutics, Inc.

Sponsor score: 0

ClinicalTrials ID:NCT06736704

Provider View

This clinical trial is testing a new drug, SNV4818, to see if it is safe and effective for treating advanced solid tumors. Researchers are exploring different doses to find the best one for patients.

Patient Parameters

Program Overview

The purpose of this study is to evaluate a new medication called SNV4818 for people with advanced cancers. The researchers aim to determine if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are testing various doses to identify the safest and most effective option.

Eligibility Criteria

Inclusion Criteria

  • Have an advanced or metastatic solid tumor with a specific PIK3CA mutation.
  • Have tried other treatments that did not work or could not be tolerated.
  • Have cancer that can be measured by scans or evaluated through specific blood tests.
  • Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

  • Have a primary cancer in the brain or spinal cord.
  • Have active cancer that has spread to the brain or the membranes covering the brain and spinal cord.
  • Have type 1 diabetes or poorly controlled type 2 diabetes.
  • Have poor organ function.
  • Have significant heart rhythm problems, including a prolonged QT interval on an ECG.

Locations

FACILITYZIPCITYSTATE
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate90025Los AngelesCalifornia
Massachusetts General Hospital02114BostonMassachusetts
Thomas Jefferson University-Sidney Kimmel Cancer Center19107PhiladelphiaPennsylvania
Sarah Cannon Research Institute37203NashvilleTennessee
The University of Texas M.D. Anderson Cancer Center77030HoustonTexas

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.